EBR SYSTEMS INC (EBR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBR - EBR SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.67
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.71

02 Oct
2023

0.025

OPEN

$0.71

3.65%

HIGH

$0.71

17,199

LOW

$0.71

TARGET
$1.395 96.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MEB . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
EBR: 1
Title FY23
Forecast
FY24
Forecast
EPS (cps) - 19.1 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 20212022
EPS Basic xxx-17.7
DPS All xxx0.0
Sales/Revenue xxx-
Book Value Per Share xxx23.9
Net Operating Cash Flow xxx-43.2 M
Net Profit Margin xxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20212022
Return on Capital Employed xxx-56.42 %
Return on Invested Capital xxx-46.87 %
Return on Assets xxx-42.77 %
Return on Equity xxx-56.42 %
Return on Total Capital xxx-46.58 %
Free Cash Flow ex dividends xxx-44.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20212022
Short-Term Debt xxx0 M
Long Term Debt xxx31 M
Total Debt xxx32 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx94 M
Price To Book Value xxx1.92

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20212022
Capex xxx1.1 M
Capex % of Sales xxx-
Cost of Goods Sold xxx1 M
Selling, General & Admin. Exp & Other xxx47 M
Research & Development xxx19 M
Investments - Total xxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

23/05/2023

1

Upgrade to Speculative Buy

$1.30

83.10%

EBR Systems has achieved the primary efficacy and interim safety end-points for its Solve-CRT product with freedom from Type 1 complications observed in 80.9% of patients.

If regulatory approval is achieved for the indications Bell Potter observes, this would provide an addressable market of about US$2bn. This decreases the risk weighting towards revenue and earnings across forecasts.

The broker upgrades to Speculative Buy from Hold and raises the target price to $1.30 from $0.70.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -21.56 cents.
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -20.53 cents.

EBR STOCK CHART